Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wouldn't be missing much if it were.
I guess it doesn't really matter.
Isn't the world going to end in December 2012? LOL
Wow look at gold today!
I used to visit that board every day just to get a few laughs. Cowboy's, Indians, and a few Wacko's.
Had some fun responding to some of their posts just to get a rise out of them. LOL
Hey Expert, If all you say is true, or even if it's not. Why are you here.
Trying to save all us poor souls from getting ripped off?
I don't think so.
It really amazes me why people who have no insterest, or investment in a stock, join a board , just to say how bad the stock is.
Please try to find another board , that someone really gives a s... about your opinions. Most of the other members of the board are doing quite well with out them.
Darby, I really enjoy your posts and charts. And this board as a whole.
I'm just a 62 yr old carpenter with a HS education, so I make no attempt at reading the charts. I've lost quite a bit on stocks in the last 10 yrs. (it's my gambling outlet). But it's all been fun money, if you know what I mean. And I think I will recoup all of it and much more on this one shortly.
GO GSPG!!!
Yes, there are a few pretty (weird) people on the Yahoo board. I do enjoy reading it sometimes just for that reason. Some to the extent of being paranoid. Sort of like the computer, end of the world, senerio that played out on 12/31/99. If you know what I mean. And they are serious. lol
DITTO
Gold Seeker, I'm so glad you are resigning. I enjoyed reading your posts before you became a moderator, but after you became one, all the good info disappeared. You spent to much time trying to keep order and not enough researching BOCX IMO. Hope you keep posting ,but from a different view.
Don't know if there's anything to this , but I've been keeping an eye on PKTX.OB for years and noticed this on their annual report that came out this morning.
Didn't know BOCX had anything to do with them anymore.
Overview
ProtoKinetix is a biologic research company based in Vancouver, British Columbia, Canada. The Company's mission is to conduct high quality medical research in order to address opportunities to treat specific conditions. All of the Company's research is conducted by third party laboratories by contracted entities and scientists in various parts of the world.
The ProtoKinetix business plan is based primarily on the furtherance of certain intellectual property rights obtained by way of "sub-licenses" of technology from other companies. At present, the Company has no product or products, and has received no patents or FDA approval for any product or diagnostic procedures.
The Company currently has no full time employees. The Company operates with a skeletal management team headed by John Todd, M.D. In addition to Dr. Todd, the Company receives advice and counsel from its Scientific Advisory Board. A short biography of Dr. Todd may be found within the document, and the biographies of other members of the ProtoKinetix Scientific Advisory Board may be found within the "Mgmt & Bios" section of the Company's website located at www.protokinetix.com.
There are two areas of research the Company is currently focused on. Below is a brief discussion of these efforts. Additionally, in order to assist you in better understanding the concepts of the Company's research, here are three definitions of some of the terms used below:
Super-Antibody This is an industry-adopted term used to describe
genetically-engineered antibodies, isolated from a
single blood cell, which have been expanded in the
laboratory to attack or have a desired effect on certain
targeted antigens, such as cancer cells.
"RECAF" or Receptor This is a carbohydrate molecule that is located on the
Alpha Fetaprotein surface of cancer cells.
"Receptor" A structure exposed on the cell surface used for
signaling or transport of molecules into the cell.
RECAF Antibody Project
The Company's first project, the development of a cancer chemotherapeutic agent based upon RECAF, a receptor for Alphafeta protein which is found on the cell surface of many types of malignant cells. The Company has a license from Biocurex, Inc. to develop superantibody therapies for the RECAF receptor site. As of the date of this report, the Company is engaged in efforts to validate the existence of the RECAF receptor site.
The Company has an agreement with BioCurex which provides us the exclusive rights to develop biologic therapies against cancer cells using: (i) the patented platform developed by InNexus; and (ii) the "conjugate approach" from Perigene.
During this past year ProtoKinetix Inc. has contracted with Dr. Dianne Damotte to conduct tests on the RECAF antibody at the George Pompidou Hospital in Paris France. The RECAF antibody was used to determine its efficacy in tagging onto cancer cells and not on to normal healthy cells. This was done to have a third party validate the claims of BioCurex and to determine the suitability of RECAF for the development of a therapeutic antibody against a variety of malignancies.
The testing by Dr. Diane Damotte demonstrated some interesting results that are still being assessed. ProtoKinetix Inc. has not yet made a decision to proceed with the development of a catalytic antibody. Further, if the Company does proceed to develop a catalytic antibody, we have not yet decided which platform to use.
The following is further discussion of the Company's RECAF R&D project :
The RECAF is a site which the Company believes exists on many cancer cells. Think of the RECAF site as a "lock on a door". Cancer cells by their very nature are antigens or foreign invaders to the way the body functions normally. The body has cells which create what are called antibodies. Antibodies are the way in which the human body attacks antigens and to cause them to die. The problem with cancer cells is that in an effort to destroy the cancer cell, it is difficult for an antibody to gain access to and bind to a cancer cell. The Company believes that should the RECAF receptor site exist, it will be able to design a superantibody (or enhanced daisy chain antibody) which will bind to the RECAF receptor site (like a key going into the lock of the door) and destroy the cancer cell.
With respect to the RECAF receptor site, on November 22, 2002, BioKinetix, Inc. entered into an agreement with BioCurex, Inc. which provided BioKinetix with exclusive world wide certain intellectual property rights to produce a therapy using superantibodies for the RECAF receptor site. On July 2, 2003, BioCurex assented to the assignment of all of BioKinetix's rights to the Company. On March 18, 2004, in consideration of the Company's commitment to issue 400,000 common shares, BioCurex executed a letter agreement ("BioCurex Letter Agreement") with the Company which made the "effective date" of the November 22, 2002, agreement - March 14, 2004. Additionally, the BioCurex Letter Agreement provided the Company with additional intellectual property rights with respect to the RECAF receptor site.
In terms of creating an antibody, the Company's efforts are being led by Professor Max Arella (please see the Company's press release dated September 4, 2003). Once an antibody is created, it must be enhanced or converted into a superantibody. In order to create a superantibody, the Company has acquired access to various technologies from (a) Innexus Corporation; and (b) Perigene Corporation.
On November 22, 2002, a BioKinetix, Inc., a research and development subsidiary of Begland Corporation, entered into an agreement with Innexus Corporation which provided BioKinetix with certain intellectual property rights to develop up to four (4) antibodies into superantibodies using the related Innexus Corporation technology. On July 3, 2003, Innexus Corporation assented to an assignment of all of BioKinetix's rights under the November 22, 2002 agreement to the Company.
On December 3, 2003, Perigene Corporation entered into an agreement with the Company whereby the Company had the right to access various Perigene intellectual property resources in order to create superantibodies.
As is discussed above, the very existence of the RECAF has yet to be determined. Both BioCurex and the Company have entered into agreement with research institutions in order to prove that a RECAF does in fact exist on some, if not many malignant cancer cells. Of course, should the RCAF not exist, the consequences to the Company and its current research efforts could be catastrophic.
Has anyone noticed this on the PKTX.OB site on their annual report?
ProtoKinetix is a biologic research company based in Vancouver, British Columbia, Canada. The Company's mission is to conduct high quality medical research in order to address opportunities to treat specific conditions. All of the Company's research is conducted by third party laboratories by contracted entities and scientists in various parts of the world.
The ProtoKinetix business plan is based primarily on the furtherance of certain intellectual property rights obtained by way of "sub-licenses" of technology from other companies. At present, the Company has no product or products, and has received no patents or FDA approval for any product or diagnostic procedures.
The Company currently has no full time employees. The Company operates with a skeletal management team headed by John Todd, M.D. In addition to Dr. Todd, the Company receives advice and counsel from its Scientific Advisory Board. A short biography of Dr. Todd may be found within the document, and the biographies of other members of the ProtoKinetix Scientific Advisory Board may be found within the "Mgmt & Bios" section of the Company's website located at www.protokinetix.com.
There are two areas of research the Company is currently focused on. Below is a brief discussion of these efforts. Additionally, in order to assist you in better understanding the concepts of the Company's research, here are three definitions of some of the terms used below:
Super-Antibody This is an industry-adopted term used to describe
genetically-engineered antibodies, isolated from a
single blood cell, which have been expanded in the
laboratory to attack or have a desired effect on certain
targeted antigens, such as cancer cells.
"RECAF" or Receptor This is a carbohydrate molecule that is located on the
Alpha Fetaprotein surface of cancer cells.
"Receptor" A structure exposed on the cell surface used for
signaling or transport of molecules into the cell.
RECAF Antibody Project
The Company's first project, the development of a cancer chemotherapeutic agent based upon RECAF, a receptor for Alphafeta protein which is found on the cell surface of many types of malignant cells. The Company has a license from Biocurex, Inc. to develop superantibody therapies for the RECAF receptor site. As of the date of this report, the Company is engaged in efforts to validate the existence of the RECAF receptor site.
The Company has an agreement with BioCurex which provides us the exclusive rights to develop biologic therapies against cancer cells using: (i) the patented platform developed by InNexus; and (ii) the "conjugate approach" from Perigene.
During this past year ProtoKinetix Inc. has contracted with Dr. Dianne Damotte to conduct tests on the RECAF antibody at the George Pompidou Hospital in Paris France. The RECAF antibody was used to determine its efficacy in tagging onto cancer cells and not on to normal healthy cells. This was done to have a third party validate the claims of BioCurex and to determine the suitability of RECAF for the development of a therapeutic antibody against a variety of malignancies.
The testing by Dr. Diane Damotte demonstrated some interesting results that are still being assessed. ProtoKinetix Inc. has not yet made a decision to proceed with the development of a catalytic antibody. Further, if the Company does proceed to develop a catalytic antibody, we have not yet decided which platform to use.
The following is further discussion of the Company's RECAF R&D project :
The RECAF is a site which the Company believes exists on many cancer cells. Think of the RECAF site as a "lock on a door". Cancer cells by their very nature are antigens or foreign invaders to the way the body functions normally. The body has cells which create what are called antibodies. Antibodies are the way in which the human body attacks antigens and to cause them to die. The problem with cancer cells is that in an effort to destroy the cancer cell, it is difficult for an antibody to gain access to and bind to a cancer cell. The Company believes that should the RECAF receptor site exist, it will be able to design a superantibody (or enhanced daisy chain antibody) which will bind to the RECAF receptor site (like a key going into the lock of the door) and destroy the cancer cell.
With respect to the RECAF receptor site, on November 22, 2002, BioKinetix, Inc. entered into an agreement with BioCurex, Inc. which provided BioKinetix with exclusive world wide certain intellectual property rights to produce a therapy using superantibodies for the RECAF receptor site. On July 2, 2003, BioCurex assented to the assignment of all of BioKinetix's rights to the Company. On March 18, 2004, in consideration of the Company's commitment to issue 400,000 common shares, BioCurex executed a letter agreement ("BioCurex Letter Agreement") with the Company which made the "effective date" of the November 22, 2002, agreement - March 14, 2004. Additionally, the BioCurex Letter Agreement provided the Company with additional intellectual property rights with respect to the RECAF receptor site.
In terms of creating an antibody, the Company's efforts are being led by Professor Max Arella (please see the Company's press release dated September 4, 2003). Once an antibody is created, it must be enhanced or converted into a superantibody. In order to create a superantibody, the Company has acquired access to various technologies from (a) Innexus Corporation; and (b) Perigene Corporation.
On November 22, 2002, a BioKinetix, Inc., a research and development subsidiary of Begland Corporation, entered into an agreement with Innexus Corporation which provided BioKinetix with certain intellectual property rights to develop up to four (4) antibodies into superantibodies using the related Innexus Corporation technology. On July 3, 2003, Innexus Corporation assented to an assignment of all of BioKinetix's rights under the November 22, 2002 agreement to the Company.
On December 3, 2003, Perigene Corporation entered into an agreement with the Company whereby the Company had the right to access various Perigene intellectual property resources in order to create superantibodies.
As is discussed above, the very existence of the RECAF has yet to be determined. Both BioCurex and the Company have entered into agreement with research institutions in order to prove that a RECAF does in fact exist on some, if not many malignant cancer cells. Of course, should the RCAF not exist, the consequences to the Company and its current research efforts could be catastrophic.
Didn't know they still had ties with PKTX.
Do they have a Denny's in Germany?
I'm sorry patty but I have to disagree. Thinking a God has any thing to do with this stock or anything making money is BS. I definitly believe in charity but not in your God. Please keep him to yourself. Besides , it is way Off-Topic.
You may be offending me. lol.
I've only got 6,000, but I'm with ya'll. Bought my first ones on 10/29/03 . 1,000 at 22c. I have a lot of patience.
Under the "Financial support for attendence it says Applications are no longer being accepted for the 2008 Annual Meeting.
Where have you been. Under a rock?
That is pretty funny. Give it up GoldSeeker. Hardly anyone on this board gives a crap what you have to say, other than your buddy Jock Strap or whatever his name is. After being on this board and the other one. I really believe you are DC Steve anyway. Now with a little news that you can't really refute, your trying to suck up. Why don't you just give up.
Raging Bull
is anyone else having trouble getting on Raging Bull? Been trying for a couple days. Go BOCX!!!
I find it more entertaining to read all the posts. Then , just not reply.